study
-
Salix initiates Target 3 phase 3 study
Salix initiates Target 3 phase 3 study to assess repeat treatment efficacy and safety of Rifaximin 550MG TID in subjects with irritable bowel syndrome with diarrhea
study | 06 April 2012
-
Bayer’s Xarelto (Rivaroxaban) meets primary efficacy endpoint, shows significant reduction in mortality in major study
Bayer HealthCare announced that the combination of oral Xarelto (Rivaroxaban) twice daily with standard antiplatelet therapy significantly reduced the composite primary efficacy endpoint of cardiovascular death, myocardial infarction and stroke in patients with acute coronary syndrome (ACS) compared to those receiving standard antiplatelet therapy alone.
study | 17 November 2011
-
Biomarkers Consortium of the FNIH selects ICON to support study evaluating variability in insulin secretory parameters
ICON, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, announced it has received a contract award from the Foundation for the National Institutes of Health (FNIH) to provide clinical support for the Biomarkers Consortium study entitled Characterization of the Variability of Insulin Secretory Parameters in the Meal Tolerance and the Maximal Stimulation Tests of Healthy Subjects.
study | 31 October 2011
-
ICON to support study evaluating variability in insulin secretory parameters
Selected by Biomarkers Consortium of the FNIH.
study | 21 October 2011
-
Roche reports positive study of Herceptin given by subcutaneous injection
Phase 3 study of a quicker route of administration shows comparable results to intravenous Herceptin.
study | 18 October 2011
-
Study shows eplerenone significantly reduced the incidence of new onset atrial fibrillation
• Study also reveals that eplerenone reduces risk of death and the risk of hospitalization among patients with systolic heart failure and mild symptoms.
study | 13 September 2011
-
Dr Reddy's starts phase 2 study with CETP inhibitor in dyslipidemia patients
Dr Reddy's Laboratories announced the initiation of dosing with DRL-17822 in patients with diagnosis of type 2 dyslipidemia. DRL-17822 is a selective, orally bioavailable inhibitor of cholesteryl ester transfer protein (CETP), for the treatment and/or prevention of dyslipidemia, atherosclerosis and associated cardiovascular disease.
study | 05 September 2011
-
AstraZeneca announces top-line results from SATURN study
AstraZeneca has announced top-line results from SATURN (Study of Coronary Atheroma by InTravascular Ultrasound: Effect of Rosuvastatin Versus AtorvastatiN). SATURN was designed to measure the impact of CRESTOR (rosuvastatin) 40 mg and atorvastatin 80…
study | 02 September 2011
-
Roche’s investigational treatment for asthma meets primary endpoint in phase 2 study
Lebrikizumab has potential to be the first personalized treatment for asthma.
study | 04 August 2011
-
Pfizer announces phase 3 study results of patients with Fibromyalgia in Japan
Pfizer Japan announced the top-line results for Lyrica (pregabalin) Study A0081208 – Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate Efficacy and Safety of Pregabalin (CI-1008) in the Treatment of Fibromyalgia. According…
study | 07 July 2011
